Physician profile
Alan K Munoz
NPI 1205865524
$3,530.06
in general payments reported to CMS, 2019-2025
36 companies · $755 in 2025
The $755 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $880 · 2020: $713 · 2021: $16.07 · 2022: $19.20 · 2023: $389 · 2024: $757 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $565.02 | 2019-2025 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $407.92 | 2020-2025 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals LP | $358.92 | 2019-2025 | Lynparza |
| Genmab U.S., INC. | $274.97 | 2023-2025 | Tivdak |
| Abbvie INC. | $243.43 | 2019-2025 | |
| Clovis Oncology, INC. | $227.12 | 2019-2020 | |
| Eisai INC. | $172.68 | 2024-2025 | |
| Spectrum Pharmaceuticals INC. | $131.48 | 2023-2025 | Rolvedon |
| Heron Therapeutics, INC. | $100.43 | 2019-2020 | |
| Foundation Medicine, INC. | $82.34 | 2020-2023 | |
| Therapeuticsmd, INC. | $69.42 | 2019-2020 | |
| Astellas Pharma US INC | $67.53 | 2023-2024 | Veozah |
| Coherus Oncology, INC. | $60.99 | 2020 | |
| Kyowa Kirin, INC. | $57.69 | 2019-2020 | |
| Tela Bio, INC. | $56.18 | 2024 | Ovitex 2s |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $54.09 | 2025 | Enhertu |
| Genentech USA, INC. | $53.54 | 2019-2020 | |
| Mylan Institutional INC. | $51.66 | 2019 | |
| Biom'Up France Sas | $44.52 | 2020 | |
| Tesaro, INC. | $44.49 | 2019 | |
| Conmed Corporation | $44.38 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.82 | 2024 | |
| Amgen INC. | $39.20 | 2019-2020 | |
| Pharmaand Gmbh | $35.17 | 2025 | Rubraca |
| Tempus Ai, INC | $29.66 | 2024 | |
| Caris Mpi, INC. | $27.93 | 2025 | Mi Cancer Seek |
| Lsi Solutions INC | $25.27 | 2024 | Fornisee |
| Janssen Biotech, INC. | $23.89 | 2024 | Remicade |
| Tei Biosciences INC | $22.44 | 2019 | |
| Tersera Therapeutics LLC | $21.01 | 2019 | |
| Millicent US INC | $19.73 | 2020 | |
| Kerecis Limited | $19.16 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Ethicon US, LLC | $16.07 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $15.74 | 2019 | |
| Tactile Systems Technology INC | $13.30 | 2020 | |
| Immunogen, INC. | $12.87 | 2023 | Elahere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.